Across TCGA pan-cancer cohorts, VPS16 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated VPS16 data layer compared with 5 for mutation status and 6 for mass-spec protein.
The strongest signal is observed in mesothelioma (MESO), where higher VPS16 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated VPS16 expression acts as an unfavorable survival marker, although some lineages such as PAAD and HNSC show a favorable association.
MESO, LGG, and LIHC are the cancer types where VPS16 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.